HealthTech Nordic member Kaiku Health has closed a €4.4 million funding round led by Swiss biopharma company Debiopharm and Finnish VC Tesi. Kaiku Health will use the funding to grow internationally and to conduct several clinical trials validating their digital therapeutics offering.
“We have seen the significant positive impact our patient monitoring platform can have on people’s health”, comments Lauri Sippola, Kaiku Health CEO and Co-Founder. “This funding allows us to provide our platform to a growing number of healthcare providers and patients internationally. It is important that our investors also bring an extraordinary understanding of healthcare, life sciences and digitalization.”
Kaiku Health is analyzing real-time health data in several medical fields, helping doctors to evaluate the effectiveness of therapies and to detect and treat health problems early on. The company’s monitoring platform is used in routine care by over 64.000 patients in Europe who thus receive more personalized care and support. Kaiku Health’s headquarters are located in Finland but the company also have offices and operations in several other Europas countries.